Articles
30.04.2020
EU P&MA implications for developments

CAR T-cell therapies and speculation in the pricing and market access implications for the lymphoma ...

Read more
Articles
24.04.2020
What are Managed Entry Agreements

Arrangements made between manufacturers and payers which are being implemented for innovative treatm...

Read more
Articles
31.03.2020
The impact of Covid-19 on payer and HTA decisions

Given the shutdown occurring in response to COVID-19, payers and HTA bodies are struggling to adjust...

Read more
Articles
27.03.2020
NICE postpones technology appraisals

NICE confirmed that they will be prioritising work that is therapeutically critical or relates to ad...

Read more
Articles
19.03.2020
What is a Payer

"Payer" generally refers to people or bodies other than the patient that finance or refund the cost ...

Read more
Articles
05.03.2020
Access to orphan drugs in the EU

Differences in market access and reimbursement processes are an important factor in determining the ...

Read more
Articles
27.02.2020
Legislative updates in France and Italy

The final details of the decree may differ from those detailed above, making the precise nature of t...

Read more
Articles
20.02.2020
What is Market Access?

"Market Access" describes activities and processes that pharmaceutical and biotech companies underta...

Read more
Articles
14.02.2020
Drug price reductions in the US

Prescription drug prices in the US rank among the highest in the world and the US spent $1220 on ph...

Read more
Articles
13.02.2020
Westminster Health Forum

The Westminster Health Forum organise senior level conferences on public policy relating to health a...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.